Aventusoft, LLC appears in FDA device records as the applicant on a single 510(k) premarket notification, K252736, for the HEMOTAG Analysis Software (HAS). The filing was received August 28, 2025, and decided October 21, 2026, with decision code SESE, described as Substantially Equivalent. The submission is a Traditional 510(k) reviewed by the Cardiovascular advisory committee under product code DQD, and FDA records a Summary rather than a statement. The same record identifies the broader trade name as the HEMOTAG Device with HEMOTAG Analysis Software, regulated as an electronic stethoscope under 21 CFR 870.1875, Class II. [1][2][7]
The cleared submission and its scope
K252736 covers the HEMOTAG Analysis Software, and the FDA correspondence in the file addresses the HEMOTAG Device with HEMOTAG Analysis Software as the trade/device name. The regulation cited is 21 CFR 870.1875, Electronic Stethoscope, Class II, product code DQD. The applicant address in the filing is Suite 300, Boca Raton, Florida 33431, matching the address Aventusoft publishes on its own site. The 510(k) database entry lists the clearance type as Traditional and the third-party review flag as No. [1][7][3]
The MedtechLedger collection contains one linked 510(k) record with one SESE decision. This count describes the linked collection at the snapshot date, rather than Aventusoft’s complete submission history or sales. The collection has no PMA, De Novo or recall entry for this applicant; that limited coverage does not establish an absence of such records elsewhere. [1]
Documented product components
A Hemotag dashboard page lists component part numbers and versions, including HEMOTAG Analysis Software 2.2.0, HEMOTAG Cloud Function - Python 2.0, HEMOTAG Clinician Dashboard 1.7.3, HEMOTAG Clinician Report, HEMOTAG Device Firmware 3.06, and Android and iOS mobile device applications. The page also gives support contact details for the product. These entries describe software and firmware components rather than clinical performance. [5]
FDA establishment registration and device listing records show AVENTUSOFT in Florida with registration number 3029300449 for 2026, listed as a manufacturer of a medical device data system covering the HEMOTAG Clinical Dashboard and HEMOTAG Mobile App. That listing is separate from the 510(k) clearance and concerns establishment registration and device listing rather than premarket review. [6]
Company identity and published positioning
Aventusoft describes itself as a privately held company in Boca Raton, Florida, active in signal detection analysis since 2010, and lists Hemotag, CarePear and Trialogy among its products. A separate about page states the company was created in 2014 to help the Department of Defense address internal bleeding on the battlefield and names the National Heart, Lung, and Blood Institute among funders. The two pages give different founding years, and neither is confirmed by FDA records. [3][4]
A Hemotag news release dated July 22, 2025, announces publication of a peer-reviewed study in Cardiovascular Science concerning non-invasive intracardiac performance data for heart failure management, and describes HEMOTAG as founded in 2024. A January 13, 2023, Aventusoft post states that HEMOTAG was accepted into NIH's RADx Tech for Maternal Health Challenge and selected for the Viability Assessment Phase. These are publisher statements about the brand and product, not FDA findings. [8][9]
Reading the record
The FDA file establishes Aventusoft, LLC as the legal applicant for one cleared software submission and as a registered establishment listing a medical device data system. It does not establish ownership of the Hemotag brand by a separate parent entity, commercial availability, customer adoption or clinical benefit. Statements about study results and challenge participation originate with the company's own publications. [1][6][8][9]

